125 related articles for article (PubMed ID: 32347900)
1. Dispensable role of CCL28 in Kras-mutated non-small cell lung cancer mouse models.
Lin D; Zhang M; Guo H; Deng Y; Zhong B; Liao F; Xu Z
Acta Biochim Biophys Sin (Shanghai); 2020 Jun; 52(6):691-694. PubMed ID: 32347900
[No Abstract] [Full Text] [Related]
2. Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.
Domingues I; Cedres S; Callejo A; Vivancos A; Martinez-Marti A; Felip E
Pulmonology; 2020; 26(1):49-50. PubMed ID: 31401029
[No Abstract] [Full Text] [Related]
3. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Zhang J; Park D; Shin DM; Deng X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
[TBL] [Abstract][Full Text] [Related]
4. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
5. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
6. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
7. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
8. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
9. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.
Wang M; Han J; Marcar L; Black J; Liu Q; Li X; Nagulapalli K; Sequist LV; Mak RH; Benes CH; Hong TS; Gurtner K; Krause M; Baumann M; Kang JX; Whetstine JR; Willers H
Cancer Res; 2017 Apr; 77(8):2018-2028. PubMed ID: 28202526
[TBL] [Abstract][Full Text] [Related]
10. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
11. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
12. Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer.
Sheridan C; Downward J
Curr Protoc Pharmacol; 2015 Sep; 70():14.35.1-14.35.16. PubMed ID: 26331885
[TBL] [Abstract][Full Text] [Related]
13. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
14. LIN28B enhanced tumorigenesis in an autochthonous KRAS
Meder L; König K; Dietlein F; Macheleidt I; Florin A; Ercanoglu MS; Rommerscheidt-Fuss U; Koker M; Schön G; Odenthal M; Klein F; Büttner R; Schulte JH; Heukamp LC; Ullrich RT
Oncogene; 2018 May; 37(20):2746-2756. PubMed ID: 29503447
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
16. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
17. KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.
Ischenko I; Zhi J; Hayman MJ; Petrenko O
Oncotarget; 2017 Mar; 8(11):17995-18009. PubMed ID: 28152508
[TBL] [Abstract][Full Text] [Related]
18. Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis.
Zheng C; Wang Y; Yang L; Zhou S; Gao Y; Li F; Feng Y; Wang Z; Zhan L; Yan Q; Zhu X; Wong KK; Chen Z; Ji H
Sci Rep; 2017 Sep; 7(1):10407. PubMed ID: 28871124
[TBL] [Abstract][Full Text] [Related]
19. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
